We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00893516
Recruitment Status : Terminated (Portfolio consolidation.)
First Posted : May 6, 2009
Last Update Posted : February 26, 2013
Information provided by (Responsible Party):
Emergent BioSolutions

Brief Summary:
Evaluation of CD4 in combination with CHO chemotherapy in subjects with nodal involvement of non cutaneous Tcell lymphoma.

Condition or disease Intervention/treatment Phase
T-cell Lymphoma Biological: CHOP + CD4 Drug: CHOP Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicentre Open-label Dose Escalation Tiral of Zanolimumab in Combination With CHOP Chemotherapy in Patients With CD4 Positive Non-cutaneous Peripheral T-cell Lymphoma With Nodal Involvement.
Study Start Date : May 2007
Primary Completion Date : October 2008
Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
CHOP chemo therapy + CD4 therapy
Biological: CHOP + CD4
Active Comparator: 2
CHOP chemotherapy
Drug: CHOP

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • study is closed to enrollment

Exclusion Criteria:

  • study is closed to enrollment

Responsible Party: Emergent BioSolutions
ClinicalTrials.gov Identifier: NCT00893516     History of Changes
Other Study ID Numbers: GEN112
First Posted: May 6, 2009    Key Record Dates
Last Update Posted: February 26, 2013
Last Verified: February 2013

Keywords provided by Emergent BioSolutions:
non cutaneous peripheral t-cell lymphoma with nodal involvement

Additional relevant MeSH terms:
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin